Please use this identifier to cite or link to this item:
Title: Contamination of Mesenchymal Stem-Cells with Fibroblasts Accelerates Neurodegeneration in an Experimental Model of Parkinson's Disease
Authors: Pereira, Márcia Cristina Leite [UNIFESP]
Secco, Mariane
Suzuki, Daniela Emi [UNIFESP]
Janjoppi, Luciana [UNIFESP]
Rodini, Carolina Oliveira [UNIFESP]
Torres, Laila Brito [UNIFESP]
Araujo, Bruno Henrique Silva [UNIFESP]
Cavalheiro, Esper Abrão [UNIFESP]
Zatz, Mayana
Okamoto, Oswaldo Keith [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Keywords: Mesenchymal stem cells
Umbilical cord
Parkinson's disease
Cell therapy
Issue Date: 1-Nov-2011
Publisher: Humana Press Inc
Citation: Stem Cell Reviews and Reports. Totowa: Humana Press Inc, v. 7, n. 4, p. 1006-1017, 2011.
Abstract: Pre-clinical studies have supported the use of mesenchymal stem cells (MSC) to treat highly prevalent neurodegenerative diseases such as Parkinson's disease (PD) but preliminary trials have reported controversial results. in a rat model of PD induced by MPTP neurotoxin, we first observed a significant bilateral preservation of dopaminergic neurons in the substantia nigra and prevention of motor deficits typically observed in PD such as hypokinesia, catalepsy, and bradykinesia, following intracerebral administration of human umbilical cord-derived MSC (UC-MSC) early after MPTP injury. However, surprisingly, administration of fibroblasts, mesenchymal cells without stem cell properties, as a xenotransplantation control was highly detrimental, causing significant neurodegeneration and motor dysfunction independently of MPTP. This observation prompted us to further investigate the consequences of transplanting a MSC preparation contaminated with fibroblasts, a plausible circumstance in cell therapy since both cell types display similar immunophenotype and can be manipulated in vitro under the same conditions. Here we show for the first time, using the same experimental model and protocol, that transplantation of UC-MSC induced potent neuroprotection in the brain resulting in clinical benefit. However, co-transplantation of UC-MSC with fibroblasts reverted therapeutic efficacy and caused opposite damaging effects, significantly exacerbating neurodegeneration and motor deficits in MPTP-exposed rats. Besides providing a rationale for testing UC-MSC transplantation in early phases of PD aiming at delaying disease progression, our pre-clinical study suggests that fibroblasts may be common cell contaminants affecting purity of MSC preparations and clinical outcome in stem cell therapy protocols, which might also explain discrepant clinical results.
ISSN: 1550-8943
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
WOS000297597800022.pdf904.96 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.